Literature DB >> 3501473

Penicillamine induced polymyositis and dermatomyositis.

G J Carroll1, R K Will, J B Peter, M J Garlepp, R L Dawkins.   

Abstract

Eight Australian cases of D-penicillamine induced polymyositis/dermatomyositis (PM/DM) are reported. In terms of clinical, pathological and electromyographic features, D-penicillamine PM/DM is similar to idiopathic PM/DM but is generally less severe. Recovery is usually rapid when D-penicillamine is withdrawn. Sera were available for study in 6 of the 8 reported cases. Two of the 6 had elevated titers of acetylcholine receptor autoantibodies. Neither of these patients had clinical signs of myasthenia gravis. In 3 of 6 patients typed for C2, no bands were detected suggesting homozygous C2 deficiency. D-penicillamine PM/DM is associated with HLA-B18, B35 and DR4 and is immunogenetically different from idiopathic PM/DM, rheumatoid arthritis and D-penicillamine myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501473

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  Beyond the joints: neurological involvement in rheumatoid arthritis.

Authors:  Cesar Ramos-Remus; Sergio Duran-Barragan; Jose Dionisio Castillo-Ortiz
Journal:  Clin Rheumatol       Date:  2011-09-20       Impact factor: 2.980

Review 2.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

Review 3.  Familial autoimmunity and the idiopathic inflammatory myopathies.

Authors:  E A Shamim; F W Miller
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 4.  Secondary Causes of Myositis.

Authors:  Sarah H Berth; Thomas E Lloyd
Journal:  Curr Treat Options Neurol       Date:  2020-10-06       Impact factor: 3.598

5.  D-penicillamine induced polymyositis causing complete heart block.

Authors:  G D Wright; C Wilson; A L Bell
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

6.  Polymyositis complicating D-penicillamine treatment.

Authors:  A O Aydintug; R Cervera; D D'Cruz; G Ramírez; R A Asherson; M A Khamashta; G R Hughes
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

Review 7.  Drug-induced rheumatic syndromes. Diagnosis, clinical features and management.

Authors:  M G Cohen; M V Prowse
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 May-Jun

Review 8.  Environmental triggers of dermatomyositis: a narrative review.

Authors:  Christina E Bax; Spandana Maddukuri; Adarsh Ravishankar; Lisa Pappas-Taffer; Victoria P Werth
Journal:  Ann Transl Med       Date:  2021-03

9.  A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.

Authors:  J H Ahn; T H Kim; K R Peck; Y W Song
Journal:  Korean J Intern Med       Date:  1993-01       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.